Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis

AbstractContext Atopic dermatitis (AD) is a common inflammatory skin disease characterized with hyperactivation of type 2 T helper (Th2) immune responses. Icariin is a flavonoid glucoside with anti-inflammatory activities, which has been used to treat multiple diseases.Objective The present study in...

Full description

Bibliographic Details
Main Authors: Wei Zhao, Huan-Huan Yu, Wei-Wei Meng, Ai-Min Liu, Bu-Xin Zhang, Ying Wang, Jie Li, Li Wang, Yu-Fu Fang
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Pharmaceutical Biology
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/13880209.2023.2244004
_version_ 1797234865873092608
author Wei Zhao
Huan-Huan Yu
Wei-Wei Meng
Ai-Min Liu
Bu-Xin Zhang
Ying Wang
Jie Li
Li Wang
Yu-Fu Fang
author_facet Wei Zhao
Huan-Huan Yu
Wei-Wei Meng
Ai-Min Liu
Bu-Xin Zhang
Ying Wang
Jie Li
Li Wang
Yu-Fu Fang
author_sort Wei Zhao
collection DOAJ
description AbstractContext Atopic dermatitis (AD) is a common inflammatory skin disease characterized with hyperactivation of type 2 T helper (Th2) immune responses. Icariin is a flavonoid glucoside with anti-inflammatory activities, which has been used to treat multiple diseases.Objective The present study investigates the underlying mechanisms by which icariin regulates Th2 responses and AD development.Materials and methods BALB/c mice were induced by DNFB to establish AD models, and injected with or without 10 mg/kg icariin for 2 weeks (i.p., daily). CD4+T cells were induced by Th2 condition to simulate AD in vitro, and also treated with or without 100 µM icariin.Results Icariin ameliorated AD-like skin lesion, manifested as a significant decrease in dermatitis scores (from 8.00 ± 1.00 to 3.67 ± 0.58), serum IgE levels (from 3119.15 ± 241.81 to 948.55 ± 182.51 ng/mL), epidermal thickness (from 93.86 ± 4.61 to 42.67 ± 2.48 µm) and infiltration of mast cells (from 60.67 ± 3.21 cells to 36.00 ± 2.65 cells). Also, icariin inactivated NLRP3 inflammasome, inhibited Th2 skewing, reduced lncRNA MALAT1 expression, but elevated miR-124-3p expression in vivo and in vitro. MALAT1 increased NLRP3 expression through targeting miR-124-3p. Knockdown of MALAT1 repressed NLRP3 inflammasome activation and mitigated Th1/Th2 imbalance in Th2-conditioned CD4+T cells, whereas both MALAT1 overexpression and miR-124-3p inhibition ablated the inhibitory effects of icariin on Th2 immune responses.Discussion and conclusions The findings further improve our understanding of the mechanism by which icariin affects AD progression, and highlights the potential of icariin in the treatment of AD.
first_indexed 2024-03-09T00:09:40Z
format Article
id doaj.art-d574f45f28714a4e967c1b8e5562260d
institution Directory Open Access Journal
issn 1388-0209
1744-5116
language English
last_indexed 2024-04-24T16:38:52Z
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Pharmaceutical Biology
spelling doaj.art-d574f45f28714a4e967c1b8e5562260d2024-03-29T11:10:26ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162023-12-016111249125910.1080/13880209.2023.2244004Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axisWei Zhao0Huan-Huan Yu1Wei-Wei Meng2Ai-Min Liu3Bu-Xin Zhang4Ying Wang5Jie Li6Li Wang7Yu-Fu Fang8Dermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaDermatology Department, The Second Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, ChinaAbstractContext Atopic dermatitis (AD) is a common inflammatory skin disease characterized with hyperactivation of type 2 T helper (Th2) immune responses. Icariin is a flavonoid glucoside with anti-inflammatory activities, which has been used to treat multiple diseases.Objective The present study investigates the underlying mechanisms by which icariin regulates Th2 responses and AD development.Materials and methods BALB/c mice were induced by DNFB to establish AD models, and injected with or without 10 mg/kg icariin for 2 weeks (i.p., daily). CD4+T cells were induced by Th2 condition to simulate AD in vitro, and also treated with or without 100 µM icariin.Results Icariin ameliorated AD-like skin lesion, manifested as a significant decrease in dermatitis scores (from 8.00 ± 1.00 to 3.67 ± 0.58), serum IgE levels (from 3119.15 ± 241.81 to 948.55 ± 182.51 ng/mL), epidermal thickness (from 93.86 ± 4.61 to 42.67 ± 2.48 µm) and infiltration of mast cells (from 60.67 ± 3.21 cells to 36.00 ± 2.65 cells). Also, icariin inactivated NLRP3 inflammasome, inhibited Th2 skewing, reduced lncRNA MALAT1 expression, but elevated miR-124-3p expression in vivo and in vitro. MALAT1 increased NLRP3 expression through targeting miR-124-3p. Knockdown of MALAT1 repressed NLRP3 inflammasome activation and mitigated Th1/Th2 imbalance in Th2-conditioned CD4+T cells, whereas both MALAT1 overexpression and miR-124-3p inhibition ablated the inhibitory effects of icariin on Th2 immune responses.Discussion and conclusions The findings further improve our understanding of the mechanism by which icariin affects AD progression, and highlights the potential of icariin in the treatment of AD.https://www.tandfonline.com/doi/10.1080/13880209.2023.2244004Th2 responsesMALAT1NLRP3miR-124-3pCD4+T cells
spellingShingle Wei Zhao
Huan-Huan Yu
Wei-Wei Meng
Ai-Min Liu
Bu-Xin Zhang
Ying Wang
Jie Li
Li Wang
Yu-Fu Fang
Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis
Pharmaceutical Biology
Th2 responses
MALAT1
NLRP3
miR-124-3p
CD4+T cells
title Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis
title_full Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis
title_fullStr Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis
title_full_unstemmed Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis
title_short Icariin restrains NLRP3 inflammasome-mediated Th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncRNA MALAT1/miR-124-3p axis
title_sort icariin restrains nlrp3 inflammasome mediated th2 immune responses and ameliorates atopic dermatitis through modulating a novel lncrna malat1 mir 124 3p axis
topic Th2 responses
MALAT1
NLRP3
miR-124-3p
CD4+T cells
url https://www.tandfonline.com/doi/10.1080/13880209.2023.2244004
work_keys_str_mv AT weizhao icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT huanhuanyu icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT weiweimeng icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT aiminliu icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT buxinzhang icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT yingwang icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT jieli icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT liwang icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis
AT yufufang icariinrestrainsnlrp3inflammasomemediatedth2immuneresponsesandamelioratesatopicdermatitisthroughmodulatinganovellncrnamalat1mir1243paxis